Catheters: Central Venous Catheter

MIGENIX Reports Second Quarter Fiscal Year 2007 Financial Results (T-Net British Columbia) - 189 weeks ago

Vancouver, BC, December 13, 2006--(T-Net)--MIGENIX (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, reports financial results for the three and six months ended October 31, 2006 and an update on its programs.

MIGENIX Reports Second Quarter Fiscal Year 2007 Financial Results (PR Newswire via Yahoo! Finance) - 189 weeks ago

MIGENIX Inc. , a clinical-stage developer of drugs for infectious and degenerative diseases, reports financial results for the three and six months ended October 31, 2006 and an update on its programs.

Cook Medical Introduces EchoTip(TM) Echogenic Needle to Improve Visibility (Business Wire via Yahoo! Finance) - 189 weeks ago

BLOOMINGTON, Ind.----Cook Medical, the world's largest privately owned medical device manufacturer, announced today the availability of the Cook EchoTip Echogenic Needle to enhance the needle's appearance during ultrasound imaging.

Nuvelo plunges 79% on drug test failure (CNN Money) - 189 weeks ago

Drugmaker halts testing of experimental blood-clot dissolver alfimeprase after it fails in late-stage studies.

Nuvelo, Bayer say alfimeprase drug trial fails (Reuters via Yahoo! News) - 189 weeks ago

An experimental blood clot dissolver by Nuvelo Inc. and its German partner Bayer failed to meet its main goal in two late-stage studies, sending the U.S. biotechnology company's shares down more than 80 percent on Monday.

Nuvelo, Bayer say alfimeprase drug trial fails (Reuters via Yahoo! Asia News) - 189 weeks ago

CHICAGO (Reuters) - An experimental blood clot dissolver by U.S. biotechnology firm Nuvelo Inc. and its German partner Bayer failed to meet its main goal in two late-stage studies, sending Nuvelo's shares off more than 80 percent in premarket trading on Monday.

Nuvelo and Bayer Healthcare Announce Phase 3 Trials of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion (RedNova) - 189 weeks ago

SAN CARLOS, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Nuvelo, Inc.

Nuvelo and Bayer Healthcare Announce Phase 3 Trials of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion (PR Newswire via Yahoo! Finance) - 189 weeks ago

Nuvelo, Inc. and Bayer HealthCare today announced top-line data demonstrating that the Phase 3 clinical trial of alfimeprase in acute peripheral arterial occlusion , known as NAPA-2 , did not meet its primary endpoint of avoidance of open vascular surgery within 30 days of treatment.

Italian Clinical Study Demonstrates Nephros' Mid-Dilution HDF Therapy As Optimal Treatment For Patients With Limited ... (Medical News Today) - 190 weeks ago

Nephros, Inc. (Amex: NEP), announced today the results of a clinical study conducted at the Maggiore Hospital in Lodi, Italy, by Jean Louis Renaux, PhD, Director of Scientific Affairs -- Bellco SPA. [click link for full article]

Ithaka Acquisition Corp. and Alsius Corporation Announce Alsius Corporation's Third Quarter 2006 Results (Business Wire via Yahoo! Finance) - 190 weeks ago

MIAMI & IRVINE, Calif.----Alsius Corporation, the market leader in intravascular temperature management, today announced financial results for the third quarter ended September 30, 2006.